Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Hold" by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have earned a consensus recommendation of "Hold" from the eight ratings firms that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $4.78.

Several research analysts have weighed in on IRWD shares. Citizens Jmp downgraded Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Jefferies Financial Group reiterated a "hold" rating and issued a $0.70 price target (down from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 price target (down from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Craig Hallum downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Finally, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

Institutional Trading of Ironwood Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Swiss National Bank grew its stake in shares of Ironwood Pharmaceuticals by 2.2% during the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company's stock valued at $1,252,000 after buying an additional 6,000 shares during the period. Teacher Retirement System of Texas grew its stake in shares of Ironwood Pharmaceuticals by 19.6% during the 4th quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company's stock valued at $190,000 after buying an additional 7,020 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter valued at $36,000. MetLife Investment Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 10.6% during the 4th quarter. MetLife Investment Management LLC now owns 89,255 shares of the biotechnology company's stock valued at $395,000 after buying an additional 8,559 shares during the period. Finally, Hsbc Holdings PLC grew its stake in shares of Ironwood Pharmaceuticals by 88.9% during the 4th quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company's stock valued at $91,000 after buying an additional 9,828 shares during the period.

Ironwood Pharmaceuticals Price Performance

Shares of Ironwood Pharmaceuticals stock opened at $0.73 on Wednesday. Ironwood Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $7.11. The company has a market capitalization of $117.45 million, a P/E ratio of -3.63 and a beta of 0.24. The business has a 50 day moving average price of $0.71 and a 200 day moving average price of $1.92.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 1.87% and a negative net margin of 9.89%. The company had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million. As a group, research analysts expect that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.